Semaglutide
Semaglutide (Wegovy/Ozempic) is a once-weekly GLP-1 receptor agonist that produced −14.9% body weight over 68 weeks in STEP-1 (Wilding 2021, n=1961) and a 20% reduction in 3-point MACE in SELECT (Lincoff 2023, n=17604). Transformative in obese T2D with cardiovascular disease; context-dependent for metabolically healthy adults; catastrophic risk floor from NAION, gastroparesis, and aspiration events.
Semaglutide scored 6.0 / 10 (👍 Worth trying) on the BioHarmony scale as a Substance → Pharmaceutical / Drug → Other Pharmaceutical.
What It Is
Once-weekly injectable GLP-1 receptor agonist. Transformative for obese T2D with cardiovascular disease. Context-dependent for metabolically healthy adults. Catastrophic risk floor triggered by NAION, gastroparesis, and aspiration events.
Type: Peptide pharmaceutical (GLP-1 receptor agonist; 32 amino acids; prescription only).
Current status: FDA-approved for T2D (Ozempic, 2017), chronic weight management (Wegovy, 2021), and cardiovascular risk reduction (SELECT trial, 2024). Available via insurance, LillyDirect direct-to-consumer, telehealth compounded, and gray-market channels.
Terminology
- GLP-1: Glucagon-like peptide-1, an incretin hormone secreted by L-cells in the distal ileum and colon in response to nutrients.
- GLP-1RA: GLP-1 receptor agonist. Drug class that activates GLP-1R; includes semaglutide, liraglutide, dulaglutide, exenatide.
- SGLT-2: Sodium-glucose cotransporter 2. Drug class for comparison (empagliflozin, dapagliflozin); acts at kidney, not incretin axis.
- HbA1c: Glycated hemoglobin. Rolling 3-month average blood glucose marker; primary glycemic endpoint across SUSTAIN and PIONEER trials.
- STEP-1 / STEP-4 / STEP-5: Wegovy obesity trial program. STEP-1 = pivotal 68-week RCT; STEP-4 = withdrawal trial; STEP-5 = 2-year extension.
- SUSTAIN-6: Ozempic cardiovascular outcomes trial in T2D (Marso 2016, n=3,297).
- SELECT: Wegovy cardiovascular outcomes trial in non-diabetic obesity with established CVD (Lincoff 2023, n=17,604).
- SURMOUNT-5: Head-to-head RCT comparing tirzepatide vs semaglutide in obesity (Aronne 2025, n=751).
- MACE: Major adverse cardiovascular events. Composite: cardiovascular death + nonfatal myocardial infarction + nonfatal stroke.
- T2D: Type 2 diabetes mellitus.
- MTC: Medullary thyroid carcinoma. Absolute contraindication for all GLP-1RAs.
- MEN2: Multiple endocrine neoplasia type 2. Inherited cancer syndrome, absolute contraindication.
- FAERS: FDA Adverse Event Reporting System. Post-market pharmacovigilance database.
- MASH: Metabolic dysfunction-associated steatohepatitis (formerly NASH).
- NAION: Non-arteritic anterior ischemic optic neuropathy. Sudden, often permanent vision loss; Hathaway 2024 flagged HR 4.28 to 7.64 on semaglutide.
- NOAEL: No-observed-adverse-effect level. Preclinical safety threshold.
- HR: Hazard ratio. Statistical measure from time-to-event analyses.
Dosing & Protocols
Dosing information is summarized from published research and community reports. This is not a prescribing guide. Consult a healthcare provider before starting any protocol.
View 3 routes and 4 protocols
Routes & Forms
| Route | Form | Clinical Range | Community Range |
|---|---|---|---|
| Subcutaneous (Wegovy, obesity) | Pre-filled single-dose pen (Wegovy, obesity indication) | 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg SC weekly over 16 to 20 weeks STEP program reference dosing. Target 2.4 mg/week for chronic weight management. | Some users plateau at 1.0 to 1.7 mg; others microdose 0.05 to 0.25 mg for longevity (no evidence) Biohacker longevity microdosing at 0.05 to 0.125 mg weekly has zero clinical evidence |
| Subcutaneous (Ozempic, T2D) | Pre-filled multi-dose pen (Ozempic, T2D indication) | 0.25 → 0.5 → 1.0 → 2.0 mg SC weekly; 7.2 mg ultra-high dose approved March 2026 Standard T2D titration. SUSTAIN and PIONEER program data. | Off-label weight loss use typically mirrors Wegovy titration Many patients receive Ozempic off-label for obesity when Wegovy is unavailable |
| Oral (Rybelsus, T2D) | Daily tablet (Rybelsus) | 3 mg × 30 days → 7 mg → 14 mg daily T2D glycemic control; lower bioavailability (~1%) requires SNAC absorption enhancer | 3 to 14 mg/day; some weight-loss use off-label Must be taken on empty stomach with ≤4 oz water, 30 min before any food or drink |
Protocols
Wegovy titration (obesity, FDA label) Clinical
- Dose
- 0.25 mg wk 1 to 4 → 0.5 mg wk 5 to 8 → 1.0 mg wk 9 to 12 → 1.7 mg wk 13 to 16 → 2.4 mg wk 17+
- Frequency
- weekly SC
- Timing
- same day each week, rotate injection site (abdomen, thigh, upper arm) package insert; pharmacokinetic half-life ~7 days supports once-weekly steady state
- Cycling
- none; indefinite chronic dosing for sustained weight maintenance
- Days Off
- none
- Duration
- indefinite; STEP 4 showed 6.9% regain within 48 weeks of discontinuation
Target 2.4 mg/week. Down-titrate if GI intolerance. Monitor for pancreatitis, gallbladder disease, retinopathy progression, depression/suicidality.
Ozempic T2D titration (FDA label) Clinical
- Dose
- 0.25 mg × 4 wk → 0.5 mg × 4 wk → 1.0 mg → 2.0 mg as tolerated
- Frequency
- weekly SC
- Timing
- same day each week package insert
- Cycling
- none; indefinite
- Days Off
- none
- Duration
- indefinite
T2D glycemic control. Monitor HbA1c quarterly, eGFR annually. March 2026: 7.2 mg ultra-high dose approved for resistant T2D.
LillyDirect / compounded microdosing (longevity, off-label) Anecdotal
- Dose
- 0.05 to 0.125 mg weekly; some users cycle 4 weeks on / 2 weeks off
- Frequency
- weekly SC
- Timing
- same day each week anecdotal only
- Cycling
- variable; no evidence base
- Days Off
- variable
- Duration
- indefinite, as tolerated
ZERO clinical evidence at these doses. Purely speculative longevity application. Dorado 2025 recall flagged contamination in compounded stocks.
Rybelsus oral T2D (FDA label) Clinical
- Dose
- 3 mg × 30 days → 7 mg × 30 days → 14 mg/day
- Frequency
- daily oral
- Timing
- empty stomach on waking, ≤4 oz water, wait 30 min before any food, drink, or medication package insert; SNAC absorption window
- Cycling
- none
- Days Off
- none
- Duration
- indefinite
T2D only. Lower bioavailability (~1%). Strict fasted administration mandatory for absorption.
Use-Case Specific Dosing
| Use Case | Dose | Notes |
|---|---|---|
| Body Composition | 2.4 mg SC weekly (Wegovy target) | Pair with resistance training and 1.6+ g/kg protein to protect lean mass |
| Blood Sugar | 1.0 to 2.0 mg SC weekly (Ozempic) | Gold-standard GLP-1RA for T2D glycemic control |
| Cardiovascular | 2.4 mg SC weekly | SELECT indication: BMI ≥27 + established CVD |
| Kidney Function | 1.0 mg SC weekly | FLOW-indicated dosing for T2D + CKD |
| Longevity | 0.05 to 0.125 mg SC weekly (off-label, no evidence) | No clinical evidence at microdose range |
How this score is calculated →
Upside (3.27 / 5.00)
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Efficacy | 25% | 4.8 | 1.200 | |
| Breadth of Benefits | 15% | 4.8 | 0.720 | |
| Evidence Quality | 25% | 4.7 | 1.175 | |
| Speed of Onset | 10% | 3.8 | 0.380 | |
| Durability | 10% | 1.5 | 0.150 | |
| Bioindividuality Upside | 15% | 4.3 | 0.645 | |
| Total | 4.270 |
Upside Rationale
Efficacy (4.8/5.0). STEP-1 (Wilding 2021, NEJM, n=1,961) delivered −14.9% body weight at 68 weeks versus −2.4% on placebo, with 86% hitting ≥5% loss and 32% hitting ≥20%. SELECT (Lincoff 2023, NEJM, n=17,604 non-diabetic) cut 3-point MACE by 20% (HR 0.80) and all-cause mortality 19% (HR 0.81). FLOW (Perkovic 2024, n=3,533) cut the kidney composite 24% (HR 0.76) and stopped early for efficacy. SUSTAIN-6 cut MACE 26% in T2D. Cohen's d for weight loss clears 0.8, the transformative threshold. Four organ systems, four hard endpoints, four independent pivotal RCTs.
Breadth of benefits (4.8/5.0). The benefit map is whole-body systemic and extends far beyond weight. STEP-1 delivered weight, glycemia, blood pressure (−4 to −6 mmHg), lipids, and hsCRP (−38%). Newsome 2021 showed MASH resolution in 59% vs 17% on placebo. SURMOUNT-OSA demonstrated measurable sleep apnea improvement. Emerging signals include alcohol, nicotine, and gambling reduction in observational data, plus pending EVOKE Alzheimer's readout. Cardiovascular mortality, kidney progression, and liver fibrosis are all moving endpoints. The reward-circuit modulation reaches into addiction phenotypes. Semaglutide is effectively a multi-system metabolic normalizer wrapped in a once-weekly injection.
Evidence quality (4.7/5.0). 60+ completed Phase 3 RCTs with 100,000+ participants enrolled cumulatively across STEP, SUSTAIN, PIONEER, SELECT, FLOW, and SURMOUNT. SELECT and FLOW both ran under independent academic steering committees. Shi 2024 network meta-analysis ranks semaglutide among the highest-efficacy GLP-1RAs with moderate-to-high GRADE certainty. Cross-geography replication across North America, Europe, and Asia. Per v0.5 evidence integrity rules: −0.5 adjustment for Novo Nordisk sponsorship of every pivotal, but academic replication, hard-endpoint wins (mortality, MACE, kidney composite), and FAERS post-market surveillance at 40,000+ reports hold the ceiling near the top of the class.
Speed of onset (3.8/5.0). Appetite suppression is detectable within 1 to 2 weeks of the first 0.25 mg dose, driven by central GLP-1R activation in hypothalamic arcuate and POMC neurons. Measurable weight loss appears by week 4 and runs roughly linear through ~60 weeks before plateauing. HbA1c drops ~0.5% by week 12 and continues through week 28. In SELECT, cardiovascular Kaplan-Meier curves separate around month 6. This is fast for obesity pharmacology, where prior agents took 6 to 12 months to show 5% weight loss. The 16 to 20 week titration to 2.4 mg is the rate-limiting step.
Durability (1.5/5.0). The single biggest weakness of the drug class. STEP-4 (Rubino 2021, JAMA, n=803) randomized participants at 2.4 mg to continue vs switch to placebo at week 20: placebo-switch regained 6.9% body weight over the next 48 weeks while continuation lost another 7.9%. STEP-1 extension showed two-thirds of lost weight regained within one year off drug. Physiological set-point defense stays fully intact; semaglutide does not reset adipostat biology. Plasma half-life ~7 days, full washout in 5 to 6 weeks. Effectively a lifetime medication, not a cure. This is why Durability scores a 1.5.
Bioindividuality upside (4.3/5.0). STEP-1 distribution is tight and high-ceiling: 86% hit ≥5% weight loss, 69% hit ≥10%, 50% hit ≥15%, 32% hit ≥20%. Non-responder rate ~14%, low by pharmacology standards. Response is consistent across age strata, sex, baseline BMI, and insulin-resistance severity. STEP-2 in T2D showed slightly attenuated effect (~10% vs 14.9% in non-diabetic), but still ceiling-clearing. Ozempic vs Wegovy response tracks dose, not biology. Real-world data (Aronne 2024 retrospective) confirms trial-consistent distribution at scale. This tight distribution is rare in obesity pharmacology and a core reason for the 4.3.
Downside (3.04 / 5.00)
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Safety Risk | 30% | 4.0 | 1.200 | |
| Side Effect Profile | 15% | 3.3 | 0.495 | |
| Financial Cost | 5% | 3.5 | 0.175 | |
| Time/Effort Burden | 5% | 1.5 | 0.075 | |
| Opportunity Cost | 5% | 2.2 | 0.110 | |
| Dependency / Withdrawal | 15% | 4.0 | 0.600 | |
| Reversibility | 25% | 2.3 | 0.575 | |
| Total | 3.230 | |||
| Harm subtotal × 1.4 | 4.018 | |||
| Opportunity subtotal × 1.0 | 0.360 | |||
| Combined downside | 4.378 | |||
| Baseline offset (constant) | −1.340 | |||
| Effective downside penalty | 3.038 |
Downside Rationale
Safety risk (4.0/5.0). Catastrophic risk floor triggered. Hathaway 2024 (JAMA Ophthalmol, Mass Eye and Ear retrospective, n=16,827) found NAION hazard ratio 4.28 in T2D and 7.64 in obese adults vs comparator agents; NAION is sudden, often permanent vision loss. Sodhi 2023 (JAMA, n=16,184) documented gastroparesis HR 9.09 and bowel obstruction HR 4.22. MDL 3094 tracks 3,500+ federal lawsuits including permanent gastroparesis. Pulmonary aspiration deaths under anesthesia are published. Acute pancreatitis class signal persists in FAERS. Rodent thyroid C-cell tumor data sits under a black box warning. The tail is severe, even if rare.
Side effect profile (3.3/5.0). Nausea affects 40 to 75% of users at therapeutic dose, with vomiting, diarrhea, and constipation clustering behind. Real-world discontinuation runs 30 to 50% per Blue Cross Blue Shield claims data versus 4 to 7% in the STEP-1 trial where titration was supervised. Patient-forum phenotypes include "Ozempic face" (rapid facial fat loss), hair shedding (telogen effluvium from rapid caloric deficit), anhedonia, and libido loss. DEXA sub-studies show up to 45% of weight lost is lean mass, which is a body-composition disaster without concurrent resistance training and 1.6+ g/kg protein intake. GI effects attenuate but rarely resolve at target dose.
Financial cost (3.5/5.0). Retail cash price in the US is $1,350/month for Wegovy and $1,000/month for Ozempic per GoodRx 2025 data. Insurance coverage is spotty and inconsistent: Medicare Part D covers Wegovy for CVD + BMI ≥27 (2025 rule), most commercial plans require PA + BMI ≥30, Medicaid coverage varies by state. LillyDirect tirzepatide is $399 to $549/month (not semaglutide, but nearest competitor). Compounded semaglutide runs $300 to $500/month through 503A pharmacies, with the Dorado 2025 recall documenting contamination risk. Gray-market "research peptides" at $150 to $300 carry sterility, potency, and endotoxin failures. Cost is a lifetime commitment given the regain dynamics.
Time/effort burden (1.5/5.0). Semaglutide is among the lowest-effort interventions in the BioHarmony dataset. Single weekly subcutaneous injection, ~5 seconds of active time, rotating between abdomen, thigh, and upper arm. Pen is pre-filled and pre-dosed; no measuring, no reconstitution. Compare to metformin (2 to 3 daily oral doses + B12 monitoring), to continuous glucose monitor protocols (sensor changes every 10 to 14 days), or to structured exercise (3 to 5 sessions/week at 30 to 90 min each). Reminder apps close the compliance loop. 16 to 20 week titration is the only time-sensitive phase; once at 2.4 mg, effort is negligible. Household storage is refrigerated, travel is unrefrigerated up to 28 days per label.
Opportunity cost (2.2/5.0). Semaglutide crowds out the adaptive lifestyle work it's supposed to pair with. Blunting food reward makes it easy to skip structured eating, which means many users never build the metabolic flexibility, protein discipline, or strength-training baseline they will need when they discontinue. STEP-4 regain dynamics expose this: if the only lever pulled was pharmacology, cessation reverses everything. Training appetite drops in many users, undercutting resistance-training compliance exactly when it's most needed for lean-mass preservation. Social eating erodes. Anhedonia reports in patient forums suggest the reward-circuit dampening extends past food. Pharmacology displaces behavior change unless the user actively resists.
Dependency/withdrawal (4.0/5.0). Two-thirds of lost weight is regained within 12 months of stopping, per STEP-1 extension. STEP-4 showed 6.9% regain over 48 weeks after week-20 placebo switch. Physiological set-point defense (leptin drop, ghrelin rise, thyroid T3 fall, NEAT suppression) stays fully intact; semaglutide does not reset adipostat biology, it suppresses hunger while the drug is on board. Plasma half-life ~7 days, steady state at 4 to 5 weeks, full washout in 5 to 6 weeks. The drug is effectively a chronic medication like a statin, not a cure. Insurance disruption, supply shortages, or side effects forcing discontinuation all trigger regain.
Reversibility (2.3/5.0). Most users can stop semaglutide and return metabolically close to baseline within a few months, once the ~5-week washout completes. Weight regain is the expected outcome, not a pathology. However, reversibility fails at the tail: NAION is permanent vision loss, not recoverable on discontinuation. Some gastroparesis cases persist post-discontinuation, with MDL 3094 documenting permanent cases in federal litigation. The 45% lean mass loss in DEXA sub-studies does not return as muscle on discontinuation; regained weight is almost entirely fat, producing a worse body composition than baseline. Chronic drug, mostly reversible, with a small tail of permanent harms.
Verdict
✅ Best for: Adults with obesity and type 2 diabetes, established cardiovascular disease plus BMI ≥27, diabetic chronic kidney disease, or severe metabolic dysfunction who have genuinely tried lifestyle intervention. SELECT showed an 81% all-cause mortality HR. If you are heading toward a cardiovascular event, semaglutide is one of the most effective drugs ever invented.
❌ Avoid if: You are a metabolically healthy biohacker chasing longevity optimization; you have a history of MTC or MEN2; you have pancreatitis history, gastroparesis, diabetic retinopathy, or eating disorder history; you are pregnant or planning to be; you cannot commit to indefinite continuous use; you are unwilling to resistance train and eat 1.6+ g/kg protein to protect lean mass; or you are sourcing from gray-market compounders without GMP sterility assurance.
Use Case Breakdown
The overall BioHarmony score reflects the intervention's primary evidence profile. These subratings are independent assessments per use case.
| Use Case | Score | Summary |
|---|---|---|
| ✅ Blood Sugar / Glycemic Control | 9.5 | Gold-standard GLP-1RA with robust A1c reduction across SUSTAIN and PIONEER trials |
| ✅ Metabolic Health | 9.0 | Comprehensive metabolic improvement: glucose, lipids, blood pressure, inflammation |
| ✅ Cardiovascular | 8.0 | SELECT trial showed 20% MACE reduction in obese non-diabetics; landmark evidence |
| 💪 Liver / Detoxification | 7.5 | Phase 2 NASH trials show significant steatosis and fibrosis improvement |
| 💪 Healthspan | 7.5 | Multi-system metabolic benefits extend functional health in metabolic syndrome |
| 💪 Anti-Inflammatory | 7.5 | Reduces CRP, IL-6, and systemic inflammation beyond weight loss effects |
| 💪 Longevity / Lifespan | 7.0 | CV mortality reduction plus metabolic normalization; long-term data still accumulating |
| 💪 Body Composition / Fat Loss | 7.0 | 15 to 17% weight loss in trials but 30 to 40% of loss is lean mass |
| 💪 Kidney Function | 7.0 | FLOW trial showed significant renal protection in diabetic kidney disease |
| 👍 Autophagy | 6.5 | Caloric restriction and GLP-1 signaling both upregulate autophagy pathways |
| 👍 Fertility (Male) | 6.5 | Weight loss improves testosterone, sperm parameters in obese men |
| 👍 Neuroprotection | 6.0 | GLP-1 receptors in brain; ongoing Alzheimer's and Parkinson's trials |
| 👍 Hormonal / Endocrine | 6.0 | Normalizes insulin, improves testosterone in obese men, restores ovulation in PCOS |
| 👍 Flexibility / Mobility | 6.0 | Significant weight loss reduces mechanical joint stress and improves mobility |
| 👍 Sleep Quality | 6.0 | SURMOUNT-OSA showed AHI reduction; weight loss improves sleep apnea |
| 👍 Pediatric Use | 6.0 | FDA-approved for adolescent obesity (12+); STEP TEENS trial data |
| ⚖️ Endurance / Cardio | 5.5 | Weight loss improves cardiorespiratory fitness but muscle loss may offset gains |
| ⚖️ Respiratory | 5.5 | Weight loss improves lung function and sleep apnea severity |
| ⚖️ Mood / Emotional Regulation | 5.5 | Improved metabolic health and body image may improve mood; some report anhedonia |
| ⚖️ Libido / Sexual Health | 5.5 | Weight loss improves sexual function in obese individuals; some report decreased appetite broadly |
| ⚖️ Mitochondrial | 5.5 | GLP-1 signaling influences mitochondrial biogenesis; weight loss reduces metabolic burden |
| ⚖️ Antioxidant / Oxidative Stress | 5.5 | Reduced metabolic stress lowers systemic oxidative burden |
| ⚖️ Cellular Senescence | 5.5 | Metabolic normalization may slow senescence-associated secretory phenotype |
| ⚖️ VO2 Max | 5.5 | Weight loss improves relative VO2max but absolute may decrease with lean mass loss |
| ⚖️ Chronic Pain Management | 5.5 | Weight loss reduces osteoarthritis pain and mechanical loading |
| ⚖️ Fertility (Female) | 5.5 | Restores ovulation in PCOS; must discontinue 2 months before conception |
| ⚖️ Immune Function | 5.0 | Anti-inflammatory effects may modulate immune function; neutral direct evidence |
| ⚖️ Cognition / Focus | 5.0 | GLP-1 receptors in hippocampus; trials ongoing but no conclusive human cognitive data yet |
| ⚖️ Memory | 5.0 | Alzheimer's trials in progress; preclinical memory improvement data |
| ⚖️ Stress / Resilience | 5.0 | Metabolic stability may improve stress response; no direct cortisol data |
| ⚖️ Anxiety | 5.0 | Mixed reports; some experience reduced food anxiety, others report new anxiousness |
| ⚖️ Depression | 5.0 | FDA monitoring for suicidality signals; improved body image vs anhedonia reports |
| ⚖️ Sleep Architecture (Deep/REM) | 5.0 | Apnea improvement may normalize sleep stages; no polysomnography architecture data |
| ⚖️ Neuroplasticity | 5.0 | GLP-1 receptor signaling in brain; preclinical neuroplasticity evidence |
| ⚖️ Energy / Fatigue | 5.0 | Some report improved energy from weight loss; others report fatigue from caloric deficit |
| ⚖️ Hearing / Auditory | 5.0 | No evidence either way; neutral |
| ⚖️ Lymphatic / Drainage | 5.0 | Weight loss reduces lymphedema burden; no direct lymphatic mechanism |
| ⚖️ Flow State / Peak Mental Performance | 5.0 | No evidence either way; neutral |
| ⚖️ Creativity / Divergent Thinking | 5.0 | No evidence either way; neutral |
| ⚖️ Methylation Support | 5.0 | No evidence either way; neutral |
| ⚖️ Heavy Metal / Toxin Burden | 5.0 | Fat loss may release stored toxins; no controlled detox studies |
| ⚖️ Electromagnetic / Frequency Therapy | 5.0 | No evidence either way; neutral |
| ⚖️ Telomere / DNA Repair | 5.0 | Metabolic improvement may slow telomere attrition; no direct data |
| ⚖️ Reaction Time / Coordination | 5.0 | No evidence either way; neutral |
| ⚖️ Geriatric / Aging Population | 5.0 | Sarcopenia risk from lean mass loss in elderly; benefit-risk requires careful assessment |
| ⚖️ Traumatic Brain Injury | 5.0 | GLP-1 neuroprotection plausible; no TBI-specific trials |
| ⚖️ Circadian Rhythm / Chronobiology | 5.0 | GLP-1 is diurnally regulated; no evidence of circadian disruption or benefit |
| ⚖️ Social Bonding / Empathy | 5.0 | Reduced food-centered socializing reported; neutral overall |
| ⚖️ Spiritual / Consciousness Expansion | 5.0 | No evidence either way; neutral |
| ⚖️ Acute Pain Relief | 5.0 | No evidence either way; not an analgesic |
| ○ Nerve Regeneration | 4.5 | GLP-1 neuroprotection data exists but no nerve regeneration evidence |
| ○ Eye / Vision Health | 4.5 | Risk of diabetic retinopathy worsening with rapid glucose improvement |
| ○ Dental / Oral Health | 4.5 | No direct benefit; some concern about GI-related enamel erosion from nausea/vomiting |
| ○ Cold / Heat Tolerance / Hormesis | 4.5 | Significant weight loss may reduce cold tolerance; brown fat effects unclear |
| ○ Recovery / Repair | 4.5 | Anti-inflammatory effects may aid recovery but caloric deficit impairs it |
| ○ Injury Recovery | 4.5 | Weight reduction helps joint recovery; caloric deficit impairs tissue healing |
| ○ Stem Cell Support | 4.0 | GLP-1 influences pancreatic beta cell regeneration; broader stem cell effects unknown |
| ○ Strength / Power | 4.0 | 30 to 40% lean mass loss compromises strength without resistance training |
| ○ Wound Healing | 4.0 | Improved glycemic control aids wound healing in diabetics; caloric deficit may impair |
| ○ HRV / Vagal Tone / Autonomic Balance | 4.0 | Increases resting heart rate 2 to 4 BPM; decreases HRV in some users |
| ○ Bone / Joint Health | 3.5 | Rapid weight loss may decrease bone density; mechanical joint relief is positive |
| ○ Hair / Nail Health | 3.5 | Caloric restriction-related hair loss reported; nutritional deficiency risk |
| ○ Skin / Beauty | 3.0 | Rapid weight loss causes loose skin; collagen loss from caloric deficit |
| ○ Muscle Growth / Hypertrophy | 3.0 | Significant lean mass loss; must pair with resistance training and high protein |
| ○ Gut Health / Microbiome | 3.0 | GI side effects (nausea, constipation, diarrhea) are most common adverse events |
Frequently Asked Questions
What is semaglutide and how does it work?
Semaglutide is a long-acting GLP-1 receptor agonist with 94% homology to native human GLP-1. It activates GLP-1R at three sites: pancreatic beta cells (glucose-dependent insulin secretion), hypothalamic arcuate and POMC neurons (satiety and appetite suppression, which drives most of the weight-loss signal), and the GI tract (delayed gastric emptying, suppressed glucagon). Plasma half-life is ~7 days, supporting once-weekly SC dosing. Branded as Ozempic (T2D, 2017), Wegovy (obesity, 2021), and Rybelsus (oral T2D, 2019). Novo Nordisk developed it; biosimilar patents expire in the mid-2030s.
How much weight loss can I expect on semaglutide?
In STEP-1 (Wilding 2021, n=1961, 68 weeks, 2.4 mg/week), mean body weight dropped 14.9% vs 2.4% on placebo. Distribution: 86% lost ≥5%, 69% lost ≥10%, 50% lost ≥15%, and 32% lost ≥20%. Non-responder rate ~14%. Head-to-head versus tirzepatide in SURMOUNT-5 (Aronne 2025, n=751, 72 weeks), tirzepatide produced 20.2% weight loss vs semaglutide's 13.7%, an absolute difference of 6.5 percentage points (p<0.001). Expect a linear weight-loss slope through ~60 weeks, then plateau.
Is semaglutide safe long-term?
The SELECT trial (Lincoff 2023, n=17,604) provides the cleanest long-term safety signal: 3-point MACE HR 0.80, all-cause mortality HR 0.81 over 3+ years, no new signals. However, FAERS has accumulated class signals: acute pancreatitis, gastroparesis HR 9.09 (Sodhi 2023), NAION HR 4.28 to 7.64 (Hathaway 2024), pulmonary aspiration deaths under anesthesia, and a rodent thyroid C-cell tumor signal carrying a black box warning. MDL 3094 tracks 3,500+ federal lawsuits. Long-term oncology and bone-density data beyond 5 years remain thin.
Who should NOT take semaglutide?
Absolute contraindications per the FDA Wegovy label: personal or family history of medullary thyroid carcinoma (MTC), multiple endocrine neoplasia type 2 (MEN2), or known hypersensitivity. Pregnancy is a hard stop (discontinue 2 months before conception; animal teratogenicity documented). Strong relative contraindications: history of pancreatitis, gastroparesis or severe GI motility disorders (Sodhi 2023 HR 9.09), active diabetic retinopathy (SUSTAIN-6 showed progression), active eating disorder, and scheduled surgery under general anesthesia within 3 weeks (aspiration risk). Biohackers chasing longevity without metabolic dysfunction are a poor risk-benefit fit.
How does semaglutide compare to tirzepatide and retatrutide?
SURMOUNT-5 (Aronne 2025, n=751, 72 weeks) is the pivotal head-to-head: tirzepatide 15 mg −20.2% body weight vs semaglutide 2.4 mg −13.7%, a 6.5 percentage point absolute difference (p<0.001). Tirzepatide also produced superior HbA1c and lipid effects. Retatrutide (Eli Lilly triple GIP/GLP-1/glucagon agonist, Phase 2 Jastreboff 2023) produced 24.2% weight loss at 48 weeks in early data, likely highest-efficacy GLP-1 class member. Tirzepatide and retatrutide have shorter safety records; semaglutide retains the most long-term outcomes data (SELECT, FLOW, SUSTAIN-6) and remains first-line for CV and renal protection.
What happens if I stop semaglutide?
Expect rapid regain. STEP-4 (Rubino 2021, JAMA) randomized participants who had reached 2.4 mg to continue vs switch to placebo at week 20: placebo-switch arm regained 6.9% body weight over the next 48 weeks while continuation arm lost an additional 7.9%. STEP-1 extension data shows two-thirds of lost weight regained within one year off drug. The physiological set-point defense stays fully intact; semaglutide does not reset adipostat biology. Plasma half-life is ~7 days; washout to near-zero takes 5 to 6 weeks. Practical implication: treat as a lifetime medication, not a cure.
LillyDirect, compounded, and gray-market telehealth: what's legit?
LillyDirect is Eli Lilly's direct-to-consumer tirzepatide channel at $399 to $549/month; not semaglutide. Novo Nordisk runs NovoCare for cash-pay Wegovy. Compounded semaglutide was legal under FDA shortage rules through May 2025; once the shortage resolved, 503A compounding pharmacies lost legal cover for mass-market semaglutide. Dorado Pharmaceutical recalled lots in 2025 for contamination. Gray-market 'research peptides' from unregulated sources carry sterility, potency, and endotoxin risks. Stick to branded product, LillyDirect for tirzepatide, or verified 503B compounders with GMP certificates of analysis.
Microdosing vs therapeutic dosing: does low-dose semaglutide work for longevity?
Microdosing at 0.05 to 0.125 mg SC weekly has zero clinical evidence base. Every pivotal RCT (STEP, SUSTAIN, SELECT, FLOW) used 0.25 mg minimum and titrated to 1.0 to 2.4 mg. At subclinical doses, GLP-1 receptor occupancy and downstream signaling are too low to replicate the metabolic, cardiovascular, or renal endpoints that justify the drug. Biohacker community enthusiasm (AgelessRx, Marek Health, Lifeforce) outruns the data. The SELECT 20% MACE reduction required full 2.4 mg dosing. Using semaglutide for longevity in the absence of obesity, T2D, or CVD is speculative and exposes users to NAION, gastroparesis, and lean-mass risk without matching benefit.
How This Score Could Change
BioHarmony scores are living assessments. New research, regulatory changes, or personal context can shift the score up or down. These are the most likely scenarios that would change this intervention's rating.
| Scenario | New Score | Tier |
|---|---|---|
| Long-term oncology signal confirmed (Safety 4.2 → 5.0, Reversibility 2.5 → 3.5) | 4.6 / 10 | ⚠️ Proceed with caution |
| Lean-mass-sparing co-agent approved (Side effects 4.2 → 3.0, Dependency 4.3 → 3.5) | 5.5 / 10 | ⚖️ Neutral |
| EVOKE Alzheimer's positive (Breadth 4.8 → 5.0, Evidence 4.5 → 4.7) | 5.2 / 10 | ⚖️ Neutral |
| NAION incidence revises upward (Safety 4.2 → 4.8) | 4.9 / 10 | ⚖️ Neutral |
Key Evidence Sources
- Wilding JPH et al. STEP-1. N Engl J Med 2021;384:989-1002.. PMID 33567185. Landmark obesity RCT (n=1961, 68 weeks). Body weight −14.9% vs −2.4% placebo. 86% hit ≥5% loss, 50% hit ≥15%, 32% hit ≥20%.
- Lincoff AM et al. SELECT. N Engl J Med 2023;389:2221-2232.. PMID 37952131. Cardiovascular outcomes RCT (n=17,604 non-diabetic BMI ≥27 + CVD). 3-point MACE HR 0.80 (−20%); all-cause mortality HR 0.81.
- Perkovic V et al. FLOW. N Engl J Med 2024;391:109-121.. PMID 38785209. Renal outcomes RCT (n=3,533 T2D + CKD). Kidney composite HR 0.76 (−24%); stopped early for efficacy.
- Marso SP et al. SUSTAIN-6. N Engl J Med 2016;375:1834-1844.. PMID 27633186. T2D cardiovascular outcomes (n=3,297). MACE HR 0.74 (−26%).
- Rubino D et al. STEP-4 withdrawal. JAMA 2021;325:1414-1425.. PMID 33755728. Withdrawal RCT: switching to placebo at week 20 caused 6.9% regain over subsequent 48 weeks.
- Hathaway JT et al. NAION risk with semaglutide. JAMA Ophthalmol 2024;142:732-739.. PMID 38985475. Mass Eye and Ear retrospective (n=16,827). NAION HR 4.28 in T2D, 7.64 in obese adults.
- Newsome PN et al. Semaglutide in NASH. N Engl J Med 2021;384:1113-1124.. PMID 33185364. Phase 2 NASH trial. MASH resolution 59% (0.4 mg) vs 17% placebo at 72 weeks.
- Shi Q et al. Network meta-analysis of GLP-1 RAs and SGLT-2 inhibitors. BMJ 2024;384:e076410.. PMID 38286487. Network meta-analysis ranking GLP-1 RAs by efficacy and safety endpoints.
- Ryan DH et al. SELECT long-term CV benefit. Nat Med 2024;30:2049-2057.. PMID 38740993. Extended SELECT analysis: sustained CV benefit across BMI and weight-loss strata.
- FDA Wegovy Prescribing Information 2024.. Official FDA label. Black box thyroid C-cell warning. Contraindications: personal/family MTC or MEN2.
- Sodhi M et al. Gastrointestinal events with GLP-1 agonists for weight loss. JAMA 2023;330:1795-1797.. PMID 37796527. Gastroparesis HR 9.09; bowel obstruction HR 4.22. Published in JAMA Research Letter.
- Aronne LJ et al. SURMOUNT-5 tirzepatide vs semaglutide head-to-head. N Engl J Med 2025;392:1087-1099.. Head-to-head RCT (n=751, 72 weeks). Tirzepatide −20.2% vs semaglutide −13.7% body weight; absolute difference 6.5 percentage points.
Other interventions for Metabolic Health
See all ratings →📊 How BioHarmony scoring works
BioHarmony translates a weighted expected-value calculation into a reader-facing 0–10 score. 5.0 is neutral (benefits and risks balance). Above 5 = benefits outweigh risks; below 5 = risks outweigh benefits.
Harm-type downsides (safety risk, side effects, reversibility, dependency) carry a 1.4× precautionary multiplier. Harm weighs more than benefit. Opportunity-type downsides (financial cost, time/effort, opportunity cost) are subtracted at face value.
Use case subratings are independent assessments of how well the intervention addresses specific health goals. They are not components of the overall score. Each subrating reflects the scorer's judgment based on use-case-specific evidence, safety, and effect sizes.
Every dimension is evaluated on a 1–5 scale, and the baseline (1) is subtracted before weighting. A perfect intervention with zero downsides contributes zero penalty rather than a residual floor, so top-tier scores are actually reachable.
EV = Upside − Downside
EV = 3.270 − 3.038 = 0.232
EV ranges from −5 to +5. Adding 7 shifts to 2–12, dividing by 12 normalizes to 0–1, then ×10 gives the 0–10 score.
Score = ((0.232 + 7) / 12) × 10 = 6.0 / 10
Further learning
13 Top Peptides Companies Review & Test 2026: Where I Buy Peptides Online
After a decade in the peptide industry, I reviewed and ranked 13 reputable peptide companies across two tiers. Your source can mean the difference…
Fat Loss Peptides & Fasting: Body Recomposition Plan
Uncover the tools in Jay Campbell's new book “30 Days to Shredz.” Discover the power of intermittent fasting and performance enhancers for rapid fat…
